U.S. markets closed
  • S&P Futures

    3,842.50
    +33.25 (+0.87%)
     
  • Dow Futures

    31,143.00
    +231.00 (+0.75%)
     
  • Nasdaq Futures

    13,057.75
    +146.75 (+1.14%)
     
  • Russell 2000 Futures

    2,234.30
    +35.10 (+1.60%)
     
  • Crude Oil

    62.55
    +1.05 (+1.71%)
     
  • Gold

    1,744.90
    +16.10 (+0.93%)
     
  • Silver

    26.93
    +0.49 (+1.85%)
     
  • EUR/USD

    1.2089
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3993
    +0.0071 (+0.51%)
     
  • USD/JPY

    106.6700
    +0.1680 (+0.16%)
     
  • BTC-USD

    46,734.23
    +443.54 (+0.96%)
     
  • CMC Crypto 200

    934.75
    +1.62 (+0.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,630.78
    +664.77 (+2.29%)
     

Should You Take Comfort From Insider Transactions At Bio-Techne Corporation (NASDAQ:TECH)?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or sell Bio-Techne Corporation (NASDAQ:TECH), you may well want to know whether insiders have been buying or selling.

What Is Insider Buying?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, rules govern insider transactions, and certain disclosures are required.

We don't think shareholders should simply follow insider transactions. But equally, we would consider it foolish to ignore insider transactions altogether. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Check out our latest analysis for Bio-Techne

The Last 12 Months Of Insider Transactions At Bio-Techne

Independent Chairman of the Board Robert Baumgartner made the biggest insider purchase in the last 12 months. That single transaction was for US$96k worth of shares at a price of US$191 each. That implies that an insider found the current price of US$208 per share to be enticing. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Bio-Techne insiders decided to buy shares at close to current prices.

Bio-Techne insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGS:TECH Recent Insider Trading, February 6th 2020
NasdaqGS:TECH Recent Insider Trading, February 6th 2020

Bio-Techne is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Bio-Techne insiders own 0.5% of the company, worth about US$41m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Bio-Techne Insiders?

The fact that there have been no Bio-Techne insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. Insiders own shares in Bio-Techne and we see no evidence to suggest they are worried about the future. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.